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Access to specialty care has been associated with improved survival in patients with liver disease but universal access 
is not always feasible. Methods of care delivery using virtual modalities including the SCAN-ECHO (Specialty 
Access Network-Extension of Community Healthcare Outcome) program were implemented by the Veterans Health 
Administration (VHA) to address this need but limited data are available on patient outcomes. We sought to evalu-
ate the efficacy of a SCAN-ECHO visit within the context of a regional cohort of patients with liver disease in the 
VHA (n = 62,237) following implementation in the Ann Arbor SCAN-ECHO Liver Clinic from June 1, 2011, to 
March 31, 2015. The effect of a SCAN-ECHO visit on all-cause mortality was compared with patients with no 
liver clinic visit. To adjust for the differences among patients who had a SCAN-ECHO visit versus those with no 
visit, propensity score matching was performed on condition factors that affect the likelihood of a SCAN-ECHO 
visit: demographics, geographic location, liver disease diagnosis, severity, and comorbidities. During the study 
period, 513 patients who had a liver SCAN-ECHO visit were found within the cohort. Patients who had completed 
a virtual SCAN-ECHO visit were more likely younger, rural, with more significant liver disease, and evidence for 
cirrhosis. Propensity-adjusted mortality rates using the Cox Proportional Hazard Model showed that a SCAN-
ECHO visit was associated with a hazard ratio of 0.54 (95% confidence interval 0.36-0.81, P = 0.003) compared 
with no visit. Conclusion: Improved survival in patients using SCAN-ECHO suggests that this approach may be an 
effective method to improve access for selected patients with liver disease, particularly in rural and underserved 
populations where access to specialty care is limited. (Hepatology 2018;68:2317-2324).
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The conventional approach to specialty consul-tation begins with a question from a primary care provider and results in an in-person visit 
between the specialist and the patient. Although this 
method has many advantages, there are also significant 
challenges. Most specialists cluster in urban tertiary 
centers, limiting access to these providers, particularly 
for rural patients with limited ability or means to travel. 
Furthermore, knowledge gaps among frontline provid-
ers, as well as other factors such as time pressures, can 
result in suboptimal patient care.(1) In response to these 
issues, Arora et al. described an approach to specialty 
care using the ECHO (Extension of Community 
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Healthcare Outcome) program.(2) The ECHO pro-
gram formed collaborative networks between aca-
demic specialists at the University of New Mexico and 
primary care providers in community-based clinics 
throughout the state to address inadequate access to 
hepatitis C therapy in rural communities. Akin to a 
virtual medicine morning report, patient cases were 
discussed through videoconferencing between the spe-
cialist team and primary care providers from multiple 
sites. Recommendations for patient care were made in 
real time and a didactic session was included during 
the conference/clinic. Continuing medical education 
credits were provided for all attendees for each con-
ference, emphasizing the distance learning compo-
nent of this model.(3) In 2011, the Veterans Health 
Administration (VHA) adopted this program to inno-
vate specialty care delivery and renamed the program 
SCAN-ECHO (Specialty Care Access Network-
Extension of Community Healthcare Outcome). The 
Veterans Affairs (VA) Ann Arbor Healthcare System 
was one of the first to implement a SCAN-ECHO 
program for chronic liver disease (CLD). All provid-
ers within our referral base were invited to participate 
in the program. We specifically queried providers to 
accept a SCAN-ECHO consult in place of an in-per-
son consult in patients who did not appear to have 
complex medical care requiring ongoing care such as 
decompensated cirrhosis. However, the decision to 
participate was determined by the provider.
Despite wide uptake of the SCAN-ECHO pro-
gram in the VHA, data are limited regarding the 
clinical impact of VA SCAN-ECHO, particularly 
on patient outcomes such as mortality.(2,4-10) We 
previously showed that an in-person specialist con-
sultation visit is associated with improved survival in 
liver disease patients.(11) This study sought to extend 
those findings by examining whether a virtual spe-
cialty SCAN-ECHO consultation visit had a sim-




The liver disease cohort was retrieved from the 
VA corporate data warehouse (CDW) and included 
any patients with a liver disease diagnosis (based on 
ICD-9 codes) in either an inpatient visit or outpatient 
encounter in the historical VISN (Veterans Integrated 
Service Network) 11, from the beginning of the Ann 
Arbor VA SCAN-ECHO Liver program on June 1, 
2011, to March 31, 2015. The historical VISN 11 was 
one of 21 regions encompassing a 90,100-square-mile 
geographic area including Michigan, central Indiana, 
and northwest Ohio that was the VA Ann Arbor 
Healthcare System referral base during the study 
period. The liver disease cohort included any patient 
who had any one of the ICD-9 codes for liver dis-
eases that might result in specialty care referral and 
were previously validated within the VHA system(11) 
(Supporting Table S1). To account for late refer-
ral bias (i.e., very sick patients who may have died 
before being able to complete an outpatient visit), 
we excluded all patients who died within 6 months 
of their index liver disease diagnosis. This analysis, 
conducted as part of the operational evaluation of the 
Ann Arbor VA SCAN-ECHO Liver Program, was 
considered to be a nonresearch quality improvement 
under VHA Handbook 1058.05. It was conducted 
with the approval of the clinical leadership at the VA 
Ann Arbor Healthcare System.
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pRIMaRy oUtCoMe
The primary outcome was all-cause mortality as 
determined by linking the patient data files with the 
Vital Status Files in the CDW. Deaths were recorded 
from the beginning of the study period ( June 1, 2011) 
until March 31, 2015.
VeteRaNS aFFaIRS SCaN-eCHo 
VISIt gRoUp
The intervention of primary interest was a VA Liver 
SCAN-ECHO consultation visit. Since the inception of 
the Ann Arbor VA SCAN-ECHO clinic in June 2011, 
the patients who were discussed at these clinics were 
tracked prospectively. A total of 520 unique patients 
had a VA SCAN-ECHO visit during the study period. 
Of these, 513 were found within the cohort that was 
extracted from the CDW. Seven were excluded because 
the only ICD 9 code they had was for abnormal imag-
ing of the gastrointestinal tract. This code was not 
included in our liver disease patient cohort, as this code 
is not specific for liver disease (Supporting Fig. S1).
No VISIt gRoUp
Within the population of patients with liver dis-
ease, we defined patients as having no visit if they 
were not in the VA SCAN-ECHO cohort and did 
not receive a traditional in-person hepatology consul-
tation visit during the study period, as indicated by 
the presence of codes in the electronic record indicat-
ing a completed liver clinic visit.
pReDICtoRS oF a SCaN-eCHo 
VISIt
Predictors of a visit were defined as follows: demo-
graphic predictors were age at diagnosis, gender, and 
race/ethnicity. Urban, rural, and highly rural patient res-
idence was determined based on VA Planning Systems 
Support Group geocoding.(12) Liver disease diagnoses 
(hepatitis B and C), cirrhosis and cirrhosis comorbidi-
ties, including ascites, spontaneous bacterial peritonitis, 
hepatorenal syndrome, variceal bleed, hepatocellular car-
cinoma, hepatic encephalopathy and thrombocytopenia, 
were identified by ICD 9 codes. Cirrhosis complications 
were defined by the presence of codes for variceal bleed-
ing, ascites, and hepatic encephalopathy. The alanine 
aminotransferase (ALT) value used was the highest 
ALT level within 365 days, but prior to diagnosis, to 
account for triggers for consultation. The bilirubin level 
used was the value closest to diagnosis date and within 
180 days prior to diagnosis to account for severity of 
liver disease. Modified Elixhauser comorbidity scores 
were calculated using diagnosis codes that were present 
365 days prior to the first liver disease diagnosis and 
excluded liver disease and alcoholism.(13) The presence 
of a procedure (i.e., abdominal computed tomography 
[CT], magnetic resonance imaging [MRI], abdominal 
ultrasound, esophagoduodenoscopy, liver biopsy, and 
paracentesis) was defined by the presence of a current 
procedural terminology code for the procedure within 
the 1 year prior to enrollment into the cohort.
StatIStICal aNalySIS
Baseline covariates were defined within 1 year of the 
index date, defined as the first appearance of any of the 
liver disease diagnosis codes. We conducted two sepa-
rate analyses: (1) a descriptive analysis of veterans in an 
unmatched cohort with a VA SCAN-ECHO visit com-
pared with those with no visit, and (2) a survival analy-
sis using a propensity score–matched cohort to evaluate 
mortality among veterans with a VA SCAN-ECHO 
visit compared with those with no visit. Analysis of vari-
ance with Tukey’s adjustment for multiple group com-
parisons was used for bivariate analyses of categorical 
and continuous predictors of access. Multivariable logis-
tic regression was performed to determine independent 
predictors of a SCAN-ECHO visit. Survival analysis 
was performed to analyze the time from index date to 
death or end of follow-up (April 1, 2015). All relevant 
variables were included in the final model regardless of 
their statistical significance in bivariate testing.
To determine whether a SCAN-ECHO visit was 
independently associated with mortality, the propensity 
score model was developed, adjusting for the likelihood 
of a SCAN-ECHO visit using a binary logistic regres-
sion on the baseline covariates. The SCAN-ECHO 
patients were matched 1:1 to patients with no visit, tak-
ing the closest or best available match without replace-
ment. The quality of the matching was assessed using 
the absolute standardized mean difference as a balance 
measure. Survival differences were computed using the 
Cox Proportional Hazard models and Kaplan-Meier 
survival curves. Additional sensitivity analyses were per-
formed after dividing the cohorts into two groups based 
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on a Fibrosis-4 (FIB-4) score as a surrogate for presence 
of advanced liver disease/cirrhosis.(14) A cutoff of greater 
than 3.25 was used to identify patients with a high 
probability of advanced liver disease.(15) All statistical 
analyses were performed using the statistical language 
R, using the packages MatchIt (for propensity matching) 
and Survival (for Cox proportional hazard modeling).
Results
DeMogRapHICS aND ClINICal 
CHaRaCteRIStICS
During the study period, 513 eligible patients 
had a VA SCAN-ECHO visit and 62,237 had no 
visit within a cohort of 67,314 patients with a liver 
disease diagnosis (Table 1, Supporting Fig. S1). A 
total of 4,564 patients had a traditional in-person 
liver clinic visit and were excluded from the no visit 
group. In comparing the characteristics of patients 
who received a SCAN-ECHO consultation versus no 
visit, the patients in the SCAN-ECHO visit group 
were more likely rural or highly rural. This reflects 
the particular affinity for providers and patients to 
use a virtual modality when patients live far from a 
specialty site. Patients with a well-characterized liver 
diagnosis such as hepatitis B, hepatitis C, cirrho-
sis, and cirrhosis complications were more likely to 
have had a SCAN-ECHO visit. This is consistent 
with prior patterns seen, in which patients who had 
taBle 1. Characteristics of the Unmatched Cohorts
VA SCAN-ECHO No visit Significance
N 513 62,237 —
Age (SD) 56.4 (11.5) 58.0 (15.2) NS
Male gender (%) 485 (94.5) 58,698 (94.3) NS
Race (%) NS
White 370 (72.1) 45,840 (73.7)
Nonwhite 104 (20.3) 12,860 (20.7)
Unknown 39 (7.6) 3537 ( 5.7)
Geographic (%) *
Urban 240 (46.8) 38,262 (61.5)
Rural 262 (51.1) 23,408 (37.6)
Highly rural 11 (2.1) 567 (0.9)
Hepatitis B (%) 14 (2.7) 434 (0.7) *
Hepatitis C (%) 225 (43.9) 7438 (12.1) *
Cirrhosis (%) 85 (16.6) 2032 (3.3) *
Cirrhosis complication (%) 22 (4.3) 774 (1.2) *
Ascites (%) 13 (2.5) 120 (2.6) *
Hepatorenal syndrome (%) 1 (0.2) 40 (0.1) NS
Spontaneous bacterial peritonitis (%) 0 (0.0) 59 (0.1) NS
Variceal bleed (%) 8 (1.6) 145 (0.2) *
Hepatic encephalopathy (%) 6 (1.2) 267 (0.4) *
Hepatocellular carcinoma (%) 9 (1.8) 332 (0.5) *
Thrombocytopenia (%) 50 (9.7) 1507 (2.4) *
ALT (U/L) (SD) 89.5 (93.6) 50.5 (98.4) *
Bilirubin (mg/dL) (SD) 0.76 (0.98) 0.65 (0.89) *
Modified Elixhauser comorbidity (SD) 0.70 (0.93) 0.62 (0.91) *
Abdominal CT (%) 110 (21.4) 10,099 (16.2) *
Abdominal MRI (%) 17 ( 3.3) 1373 (2.2) NS
Abdominal ultrasound (%) 288 (56.1) 9403 (15.1) *
Esophagoduodenoscopy (%) 61 (11.9) 3343 (5.4) *
Liver biopsy (%) 9 (1.8) 288 (0.5) *
Paracentesis (%) 1 (0.2) 252 (0.4) NS
*P value < 0.05.
Abbreviation: NS, nonsignificant.
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these diagnoses were more likely to have a specialty 
consultation leading to a visit.(11) Similarly, patients 
with indicators suggestive of more severe liver disease 
such as elevated ALT and bilirubin were more likely 
to have had a SCAN-ECHO visit than no visit. The 
SCAN-ECHO visit group also had more imaging or 
endoscopic procedures, which is consistent with our 
prior reports that patients who had specialty consul-
tation were more likely to have more imaging stud-
ies and procedures.(11) In the multivariable analysis, 
the likelihood of having a SCAN-ECHO visit was 
increased in patients who were younger, who lived in 
a rural location, who had an ultrasound performed, or 
who had a diagnosis of cirrhosis complication, hepati-
tis C, or thrombocytopenia.
IMpRoVeD SURVIVal aMoNg 
patIeNtS WItH lIVeR DISeaSe 
DIagNoSIS aND HaVINg HaD a 
SCaN-eCHo VISIt
The effect of a SCAN-ECHO visit on all-cause 
mortality was compared with patients with no visit. 
To adjust for the differences among patients who 
had a SCAN-ECHO visit versus no visit, propensity 
score matching was performed. Propensity scores were 
developed on factors that affect the likelihood of a 
SCAN-ECHO visit (Table 1). The balance of match-
ing is illustrated in Fig. 1 (SCAN-ECHO versus no 
visit). In the matched cohorts, patients who had a 
SCAN-ECHO visit had significantly improved sur-
vival as compared with those who had no visit (Fig. 2). 
Compared with having no visit, matched patients 
who had consultation through the SCAN-ECHO 
program were associated with decreased risk of death 
(hazard ratio 0.54, 95% confidence interval 0.36-0.81, 
P = 0.003), with a 46% decreased likelihood of dying 
compared with the matched patients who had no visit 
during the follow-up period. Although our primary 
comparison was between those patients who had a 
SCAN-ECHO visit versus those who had no visit, we 
also examined whether specialty care delivery using 
SCAN-ECHO might result in a different survival 
benefit than those with an in-person visit. We found 
that using the same propensity score matching meth-
ods that matched cohorts of patients with SCAN-
ECHO visits and traditional in-person liver visits had 
similar survival (Supporting Fig. S2).
FIg. 1. Absolute standardized mean difference of the baseline covariates between patients with a SCAN-ECHO visit versus no visit.
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To examine whether the reduction in mortality was 
only seen in patients with advanced liver disease or 
all patients, we divided the matched cohorts by their 
FIB-4 score. In the propensity-matched cohorts, a 
SCAN-ECHO visit was associated with reduced 
risk of death in patients with and without advanced 
fibrosis. A SCAN-ECHO visit was associated with 
a decreased risk of death compared with those with 
no visit, with a hazard ratio of 0.40 in the cohorts of 
patients whose FIB-4 was greater than 3.25 (n = 260, 
P = 0.0004) and 0.42 in patients whose FIB-4 score 
was less than 3.25 (n = 676, P = 0.03). The analysis was 
performed only on patients who had complete data 
for FIB-4.
To examine whether the matched cohorts had dif-
ferences in alcohol intake, we examined the Alcohol 
Use Disorder Identification Test-C (AUDIT-C) 
scores in the propensity-matched cohorts. The 
AUDIT-C scores are widely implemented within the 
VHA and are mandated as a performance measure.(16) 
This simple, three-question questionnaire has been 
validated within and outside the VHA for identifying 
patients with alcohol use disorder.(17,18) We found in 
our matched cohorts that the AUDIT-C scores were 
similar between those with a SCAN-ECHO visit 
and those with no visit (1.96 ± 2.93 versus 1.93 ± 2.73, 
P > 0.05).
Seeking potential mechanisms for improved sur-
vival, we examined the relative frequency of hepa-
tocellular carcinoma (HCC) surveillance (defined 
as an abdominal imaging study at least once a year) 
and variceal surveillance (defined as an esophagogas-
troduodenoscopy (EGD) at least every 3 years) in 
the unmatched cohort of patients with FIB-4 scores 
greater than 3.25. We found that those with a SCAN-
ECHO visit had a higher rate of HCC (42% versus 
25%) and variceal surveillance (25% versus 15%) com-
pared with those with no visit.
Discussion
Novel strategies are needed to provide specialty 
care to patients with complex liver disease whose 
access is limited by geographic distance from referral 
centers. We evaluated the SCAN-ECHO program, 
a virtual form of electronic consultation, which com-
bines real-time consultation with didactic learning for 
front-line providers. In this large regional cohort of 
patients with liver disease, we found that patients who 
FIg. 2. Kaplan-Meier survival curve between those with a SCAN-ECHO versus propensity-matched cohort of patients with no visit.
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received consultation through the SCAN-ECHO 
program had improvements in several measures of 
care quality and higher survival rates than patients 
who had no specialty care visit. These data extend 
the findings of prior studies in which we and others 
have found a benefit of access to traditional, in-person 
specialty care consultations in patients with liver dis-
ease.(11,19-21) Previously, the ECHO(2,22-24) and other 
more traditional (involving direct patient to pro-
vider contact)(25,26) telemedicine programs have been 
reported, with some showing effectiveness for treating 
hepatitis C both within and outside of the VHA with 
equal outcomes. In this study, we extend the impact of 
SCAN-ECHO beyond hepatitis C therapy to show 
that this intervention is associated with improved sur-
vival for patients with all liver diseases.
Beyond the novelty of the intervention, we found 
several strengths in these analyses. First, we found 
benefit even after applying propensity matching using 
broad demographic and clinical characteristics to 
adjust for effect estimates. Second, we demonstrated 
clinically significant improvements in screening pro-
cedures and enhanced survival benefit for patients 
with elevated FIB-4 scores (indicating cirrhosis), 
establishing a mechanism for the observations. Third, 
based on the Kaplan-Meier analysis, the improved 
outcomes that are specific to the SCAN-ECHO 
program emerge after 1 year, suggesting both equal 
matching at baseline and plausible effects based on 
the types of intervention differences that may have 
resulted from specialist consultation (i.e., varices or 
HCC screening).
These data must be interpreted in the context of 
the study design. First, the consultations addressed 
many issues for patients with diverse liver diseases. 
Accordingly, the underlying mechanism for gener-
alized improvement in mortality is not clear from 
these data. We present analyses, however, that demon-
strate beneficial effects for patients at the highest 
risk of death, namely those with possible cirrhosis 
(FIB-4 > 3.25). Specifically, we show that SCAN-
ECHO is associated with improved process measures 
such as screening for liver cancer and varices that could 
be linked to improved survival. Furthermore, although 
patients were not randomized to receive either form 
of consultation, we adjusted for confounders using 
propensity-score matching. Although every attempt 
was made to match patient characteristics between 
control and cases, certain features such as patient 
socioeconomic status were not completely available. 
There is always the concern that we did not account 
for all patient differences or eliminate confounding 
by indication. Second, our propensity matching only 
accounted for patient factors. It is possible that the 
difference may be due to provider-level factors that 
are not accounted for here. All providers within our 
referral base were offered the option to participate in 
the program. However, as all consultations were vol-
untary, the choice to accept the use of the SCAN-
ECHO visit on the part of the front-line provider 
may reflect providers with baseline-elevated knowl-
edge or interest in practice improvement. We plan to 
study this as a possible mechanism for improved sur-
vival. In addition to intrinsic provider differences, the 
ECHO program may allow for more effective dissem-
ination of patient-specific information or improved 
knowledge base. A prior study on the improvement 
of knowledge base using provider surveys has shown 
surprising dissemination of liver knowledge.(27) Third, 
these data reflect the VA experience, which is a fully 
integrated healthcare system with a unique popula-
tion. Both factors may constrain the generalizability 
of these findings to other settings. Regulatory issues 
such as state-specific licensing and legal issues such 
as malpractice may be limitations in non-VA settings.
In a highly integrated healthcare system, an 
approach such as the SCAN-ECHO program may 
be an effective, scalable method to improve access for 
selected patients with liver disease, particularly in rural 
and underserved populations where access to specialty 
care is limited.
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